Search clinical trials for: LoDAC (Low Dose Cytarabine)

Total 1849 results

Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Boehringer Ingelheim

Completed

Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours

Neoplasms

Japan
Genocea Biosciences, Inc.

Completed

Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine

Streptococcus Pneumoniae

United States
Pfizer
Thrombolysis In Myocardial Infarction (TIMI)

Recruiting

A Study of Ponsegromab in People With Heart Failure (GARDEN TIMI 74)

Heart Failure

United States, Canada, China, Australia, Spain, Japan, Czechia, Hungary, Germany, United Kingdom, Poland
Mario Negri Institute for Pharmacological Research
Ministry of Health, Italy; Azienda Ospedaliera San Gerardo di Monza

Active, not recruiting

Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (STANDLOW)

Epilepsies, Partial

Italy
KBio Inc

Completed

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults

Influenza

United States
Alkermes, Inc.

Completed

A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia

Schizophrenia

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy

Painful Diabetic Peripheral Neuropathy

Germany, Hungary, Poland
King Faisal Specialist Hospital & Research Center

Unknown

Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC

Nasopharyngeal Cancer
Jiangsu Province Centers for Disease Control and...
West China Hospital

Completed

A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)

COVID-19

China
Kolon TissueGene, Inc.

Not yet recruiting

Study to Determine the Safety and Tolerability of TG-C in Subjects With Back Pain Due to Degenerative Disc Disease

Degenerative Disc Disease
Universidad Católica San Antonio de Murcia

Not yet recruiting

Blood Bioavailability of Two Different Doses of a β-alanine Supplement (BIo-β) (Bio-β)

Bioavailability

Spain
Amicus Therapeutics

Active, not recruiting

Gene Therapy for Children With CLN3 Batten Disease

Batten Disease | CLN3

United States
The University of Texas Health Science Center,...
National Center for Advancing Translational Sciences (NCATS)

Completed

Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation (TTNS-RCT)

Chronic Spinal Cord Injury | Neurogenic Bladder

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

EPP | XLP

Spain, United States, Germany, Norway, Italy, Australia, Canada, Japan, Sweden, United Kingdom
Riphah International University

Completed

Dose Response of Neural Mobilization on Hamstring Flexibility in Low Back Pain

Non-specific Low Back Pain

Pakistan
Iowa State University
National Institute of Mental Health (NIMH)

Recruiting

RESISTance Exercise for Depression Trial (RESIST)

Major Depressive Disorder

United States
Morten Hostrup, PhD

Recruiting

U-LABA/ICS Effects on Exercise Performance, Indacaterol

Exercise Performance

Denmark
Greenyn Biotechnology Co., Ltd.
Taipei Medical University

Recruiting

Effectiveness of Pumpkin Seed Extract on Improving Blood Sugar Level in Subhealth Subjects

Diabetes | Metabolic Disease

Taiwan
AxeroVision, Inc.

Completed

Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction

Meibomian Gland Dysfunction | Posterior Blepharitis

United States
The University of Texas Health Science Center,...
Samsung Electronics

Completed

Validation of a New Post Image Processing Engine (S-Vue™) for the Reduction of Ionizing Radiation Dose on X-ray Examination in Pediatric Patients

Chest X-ray for Clinical Evaluation

United States
Boehringer Ingelheim

Completed

Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers

Healthy
Jiangsu Province Centers for Disease Control and...
Beijing Institute of Biotechnology; Tianjin Cansino Biotechnology Inc

Completed

A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.

Ebola Virus Disease

China
AbbVie
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

Psoriasis

United States, Germany, United Kingdom
Appalachian State University

Recruiting

Hemp Fiber Ingestion and Gut Permeability After Exercise

Gastrointestinal Dysfunction | Metabolic Disturbance

United States
Nobelpharma

Completed

A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection

Cytomegalovirus Disease

United States, Japan
Visterra, Inc.
Biomedical Advanced Research and Development Authority

Completed

Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A

Influenza

United States, Estonia, South Africa, Bulgaria, Serbia, Ukraine, Latvia
Boehringer Ingelheim

Completed

Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4/5 Metabolism in Healthy Volunteers

Healthy

Switzerland
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Cystic Fibrosis
Boehringer Ingelheim

Terminated

Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered to Healthy Human Subjects

Healthy
OcuNexus Therapeutics, Inc.

Completed

A Study to Investigate the Efficacy, Safety and Tolerability of Nexagon® as a Topical Treatment for Subjects With Venous Leg Ulcers (NOVEL2)

Venous Leg Ulcers

United States, New Zealand, South Africa, Australia
Ariston Pharmaceuticals, Inc.

Unknown

Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine

Migraine | Migraine Disorders | Migraine Headache | Migraine Without Aura | Migraine With Aura

Finland, Netherlands, United Kingdom
Assistance Publique - Hôpitaux de Paris
Iltoo Pharma

Completed

Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers (HEALTHIL-2)

Healthy Volunteers

France
Uppsala University
Centrallasarettet Västerås; Mora Hospital, Landstinget Dalarna

Completed

Diagnostics in Diverticulitis (DIDit)

Diverticulitis

Sweden
First Affiliated Hospital Xi'an Jiaotong University
Eureka Therapeutics Inc.

Unknown

Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies

B-Cell Malignancies
OcuNexus Therapeutics, Inc.

Completed

A Study to Investigate the Safety and Clinical Effect of Nexagon® as a Topical Treatment for Subjects With a Diabetic Foot Ulcer (DUNE) (DUNE)

Diabetic Foot Ulcers

Russian Federation, United States, Ukraine
Boehringer Ingelheim

Completed

BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis

Pulmonary Disease, Chronic Obstructive

Germany
National Cancer Institute, Egypt

Recruiting

Low Dose Versus High Dose Methylene Blue in Septic Patients

Septic Shock

Egypt
Akeso

Terminated

A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer

Ovarian Neoplasms | Ovarian Cancer | Recurrent Ovarian Carcinoma | Relapsed Ovarian Cancer

China
Trinomab Biotech Co., Ltd.

Completed

Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers

Tetanus

China
USDA, Western Human Nutrition Research Center
Sonomaceuticals LLC

Completed

Metabolic Response to Chardonnay Grape Marc Powder

Obesity | Dyslipidemia

United States
Kiromic BioPharma Inc.
Statistics & Data Corporation; Stiris Research Inc

Recruiting

Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Stage 4 Metastatic NSCLC

Carcinoma, Non-Small-Cell Lung

United States
Centro di Riferimento Oncologico - Aviano

Recruiting

Use of Pulsed Low-dose Rate Re-irradiation for Recurrent Glioma (PULSAR) (PULSAR)

Glioma

Italy
M.D. Anderson Cancer Center

Recruiting

A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma

Lymphoma

United States
Centre Hospitalier Universitaire de Nīmes

Not yet recruiting

Image Quality: Ultra-Low Dose Scanner Versus Standard Dose Conventional Scanner for Thoraco-abdominopelvic Scans (UL2DLR)

Lung Diseases | Bone Diseases | Pelvis Disease | Abdomen Disease | Imaging, Diagnostic
University of Leeds
The Leeds Teaching Hospitals NHS Trust; University of Cambridge; Yorkshire Cancer...

Active, not recruiting

Yorkshire Kidney Screening Trial (YKST)

Renal Cell Carcinoma

United Kingdom
Yang Yang

Unknown

Pulsed Low Dose Rate Radiation Therapy for Gastric Cancer Patients With Peritoneal Metastasis

Stomach Neoplasms | Radiotherapy Side Effect | Radiotherapy

China
Indiana University
National Institute of Mental Health (NIMH)

Completed

Role of Exercise in Depression in Middle Aged and Older Adults (RED)

Depression

United States
H. Lundbeck A/S

Terminated

Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease

Alzheimer Disease

Austria, Finland, Sweden

Search clinical trials for: LoDAC (Low Dose Cytarabine)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations